FOLH1 and cancer: Our data further show that [64Cu]Cu-NOTA-TP-PSMA 1 outperforms its monomeric analogues, with 2.7-fold higher internalization compared to [64Cu]Cu-NOTA-PSMA and 1.2-fold higher than [64Cu]Cu-NOTA-TP in cancer cells at 24 h (Table 2).